Investigational drug · Phase 2
Keynatinib
Also called: TL007
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-Small Cell Lung Cancer With EGFR Mutation, Brain Metastases.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "Keynatinib"
First trial start
2020
Oct 21, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Keynatinib", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-Small Cell Lung Cancer With EGFR Mutation
- Brain Metastases
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Keynatinib" as an intervention, largest first.
- Phase Ib Clinical Study of KeynatinibRecruiting
Medolution Ltd.Industry
NCT04807881 · 75 participants (planned) · Start Sep 24, 2020 · Primary completion Oct 10, 2032
Drug: Keynatinib · For: Lymphoma, B-Cell
Sites: Beijing, China; Shanghai, China; Chengdu, China · 4 sites in all
Medolution Ltd.Industry
NCT04824079 · 16 participants · Start Oct 21, 2020 · Primary completion Dec 10, 2024
Drug: Keynatinib · For: Non-Small Cell Lung Cancer With EGFR Mutation; Brain Metastases
Sites: Beijing, China; Fuzhou, China; Zhengzhou, China · 5 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-Small Cell Lung Cancer With EGFR Mutation
- FirmonertinibAST2818Phase 34 trials
Allist Pharmaceuticals, Inc. · Non-Small-Cell Lung Cancer, Metastatic Non-Small-Cell Lung Cancer, Advanced Non-Small-Cell Lung Cancer
- ABSK043Phase 24 trials
Abbisko Therapeutics Co, Ltd · Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive, HER2-Gastric/Gastroesophageal Junction Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.